Larimar Therapeutics to host investor event on June 29
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 7/23/2026
- Wall St falls as tech earnings spark AI spending worries; oil hits $100
- Google increases capex forecast again after cloud-driven quarterly beat
- As Musk pivots beyond cars, Tesla’s autos engine is under strain
- RTX stock jumps as company lifts guidance after Q2 beat
- Dollar hits new 40-year high versus yen, euro lower after ECB decision
Larimar Therapeutics Announces Investor Event on the Nomlabofusp Program for Friedreich’s Ataxia
June 26, 2026 4:05 PM EDTWebcast on Monday, June 29, 2026, at 7:45 am ET
BALA CYNWYD, Pa., June 26, 2026 (GLOBE NEWSWIRE) -- Larimar Therapeutics, Inc. (Larimar) (Nasdaq: LRMR), a clinical-stage biotechnology company focused on developing treatments for complex rare diseases, today announced that the Company will host an investor event to discuss updates for the Companys nomlabofusp clinical development program including a regulatory update and data from the ongoing long-term open label study for the treatment of Friedreichs ataxia on Monday, June 29, 2026 at 7:45 am ET.
Webcast... More
